Replimune had every reason to think this was going to work.

Breakthrough Therapy Designation. Priority Review. A fully hired commercial team ready to launch. A PDUFA date of April 10, 2026, circled on the calendar for months.

Then the FDA said no.

The agency issued a Complete Response Letter for RP1 (vusolimogene oderparepvec), declining to approve the Biologics License Application under the accelerated approval pathway.

RP1 is an oncolytic HSV-1 virus that triggers cancer cell death while also forcing them to express GM-CSF to kick the immune system into gear.

Combined with Bristol Myers Squibb’s nivolumab, it posted a 34% objective response rate in the IGNYTE trial, with responses lasting a median of 24.8 months in patients whose melanoma had already progressed on anti-PD-1 therapy.

Those are the same data that earned the Breakthrough Therapy Designation in the first place.

Replimune isn’t taking it quietly…they’re pretty upset, actually.

The company says the existing data should be sufficient for accelerated approval and disputes the FDA’s determination. But disputing and winning are two different things.

To make things worse, the fallout is already happening.

Replimune announced it will scale back U.S. manufacturing operations and eliminate jobs. The company said the quiet part out loud: without timely accelerated approval, continued development of RP1 is no longer commercially viable.

That’s a brutal sentence for a company that raised $125 million in November 2024 and had cash runway into Q4 2026. The clock was always ticking, and the FDA stopped it.

Don’t worry – there is some good news – the broader pipeline isn’t dead.

RP2 is in Phase 2/3 for metastatic uveal melanoma and hepatocellular carcinoma.

RP3, the next-generation candidate loaded with anti-CTLA-4, CD40L, and 4-1BBL payloads, is in Phase 1.

The CERPASS trial is enrolling 180 patients with cutaneous squamous cell carcinoma. There’s still a company here.

But the commercial engine was built for RP1. The team was hired for RP1. The manufacturing was scaled for RP1. RP1 was their favorite kid…and the FDA killed it… I probably could have used a different analogy.

The broader oncolytic virus space is a bit schizophrenic right now.

Theriva Biologics is pushing VCN-01 toward a pivotal trial in pancreatic cancer.

Oncolytics Biotech picked up Fast Track Designation for pelareorep in colorectal cancer.

And we’re tracking over 100 OV-based companies…but it doesn’t really seem like there’s any SIGNIFICANT good news coming out of the space.

Amgen’s T-VEC remains the only FDA-approved oncolytic virus, and it was approved over a decade ago.

Replimune bet everything on the accelerated pathway because the confirmatory Phase 3 (IGNYTE-3) is still enrolling. The FDA apparently wanted to wait for it and the company couldn’t afford to.

That gap between regulatory timelines and biotech cash runways? We all know, it has a body count (not in the Jersey shore kind of way – more like The Sopranos).